Compare · ARGX vs BCAB
ARGX vs BCAB
Side-by-side comparison of argenx SE (ARGX) and BioAtla Inc. (BCAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BCAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 10009.9x BCAB ($5.5M).
- Over the past year, ARGX is up 49.5% and BCAB is down 86.6% - ARGX leads by 136.1 points.
- BCAB has been more active in the news (6 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 8 for BCAB).
- Company
- argenx SE
- BioAtla Inc.
- Price
- $872.77-2.13%
- $3.35-5.50%
- Market cap
- $55.32B
- $5.5M
- 1M return
- +10.86%
- -28.57%
- 1Y return
- +49.55%
- -86.60%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
BioAtla Inc.
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest BCAB
- Chief Financial Officer Vasquez Christian covered exercise/tax liability with 257 shares, decreasing direct ownership by 2% to 10,347 units (SEC Form 4)
- Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 898 shares, decreasing direct ownership by 2% to 52,294 units (SEC Form 4)
- Chief Medical Officer Sievers Eric covered exercise/tax liability with 494 shares, decreasing direct ownership by 1% to 11,840 units (SEC Form 4)
- SEC Form DEFA14A filed by BioAtla Inc.
- SEC Form DEF 14A filed by BioAtla Inc.
- Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
- SEC Form 10-Q filed by BioAtla Inc.
- Amendment: SEC Form 10-K/A filed by BioAtla Inc.
- BioAtla Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by BioAtla Inc.